Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: levonorgestrel Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

NCT07794150
View directory record Official record
Conditions
Menopause, Healthy Female Participants
Interventions
Estradiol/Levonorgestrel Transdermal System
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

NCT00360490
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112
View directory record Official record
Conditions
Contraception
Interventions
LCS12, LCS16
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
57
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 11, 2026, 7:27 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

NCT00995150
View directory record Official record
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 11, 2026, 7:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

NCT01192490
View directory record Official record
Conditions
Contraception
Interventions
Lidocaine, Lubricant
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2009 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Elenestinib in Healthy Adult Female Participants

NCT07388511
View directory record Official record
Conditions
Healthy Participants
Interventions
Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 11, 2026, 7:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

LARC Forward Contraceptive Counseling at MHCC

NCT02735551
View directory record Official record
Conditions
Contraception
Interventions
Long Acting Reversible Contraception (LARC), Referral for Long Acting Reversible Contraception (LARC), Prescription for Short-Acting Hormonal Contraception
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
17 Years to 30 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gresham, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 11, 2026, 7:27 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions
EE 30mcg/LNG 150mcg, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 11, 2026, 7:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantification of Immune Cells in Women Using Contraception (CHIC II)

NCT01873170
View directory record Official record
Conditions
HIV, Immune Cells (Mucosal and Systemic), Contraception
Interventions
levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Early Postpartum Intrauterine Contraception

NCT00997932
View directory record Official record
Conditions
Unplanned Pregnancy
Interventions
Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 11, 2026, 7:27 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

NCT03557619
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Venetoclax, ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 11, 2026, 7:27 AM EDT
Completed No phase listed Observational

Hormonal Influences on Inflammatory Bowel Diseases

NCT05610527
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions
Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

NCT07739589
View directory record Official record
Conditions
Residual Drug Amount of EE and LNG
Interventions
Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

NCT02477202
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Mirena® intra-uterine device (IUD)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 11, 2026, 7:27 AM EDT
Withdrawn Not applicable Interventional

Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period

NCT01088178
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 11, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

NCT02035787
View directory record Official record
Conditions
Complex Atypical Hyperplasia, Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 11, 2026, 7:27 AM EDT